The global aptamers market is oligopolistic in nature, led by key players such as Somalogic, Inc., Aptamer Sciences, Inc. and Aptagen, Inc. The top three companies account for 57.8% of the market in 2012. These companies are investing continually in research and development in order to develop novel aptamers for use in various applications such as therapeutics and diagnostics. Companies are striving to gain a better understanding of human biology and diseases, discovery of new drugs, and the development of new diagnostic tests. Companies such as Aptamer Sciences, Inc. provide high quality and cost effective custom aptamers to target various molecules based on specific customer requirements. The company offers more than 200 validated DNA aptamer sequencing for a variety of human target proteins. A new report by Transparency Market Research (TMR) states that antibodies are expected to be a major threat for the aptamers market. As the market for antibodies is well-established, researchers are reluctant to switch to the underdeveloped aptamers market. Thus, the threat of substitute is expected to be high to medium.
Read Full Report: http://www.transparencymarketresearch.com/aptamers-market.html
According to the report, the global aptamers market is expected to reach US$4,333.0 mn by 2019. On the basis of type, the nucleic acid aptamers market is expected to lead and be worth US$4,333.0 mn by 2019. By application, the market is expected to be led by the therapeutics development segment, which is likely to be worth US$1,452.4 by 2019. This segment is also likely to be expand at the maximum CAGR from 2013 to 2019. On the basis of geography, the market is expected to continue to be led by North America. The North America aptamers market is estimated to reach US$2,029.1 mn by 2019 owing to increasing scientific research and development activities by key players for the development of aptamers.
Rising Support from Various Organizations to Drive Aptamers Market
Aptamers have a great potential and thus, many private organizations in the U.S. and the U.K. are engaged in funding and further development of the aptamer field. This is expected to drive the growth of the market. Aptamers are increasingly being perceived as an attractive solution for research applications owing to the unique production methodology. The production of aptamers do not require animals, thus avoiding animal abuse and death. This eliminates the need for companies to send animal protocol the Institutional Animal Care and Use Committee (IACUC) for aptamer development. Another factor driving the market is the high specificity and selectivity of aptamers, owing to which, the volume required for analysis can be reduced. This helps in increasing the speed of the research analysis, driving their demand.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1335
Lack of Formal Regulatory Guidelines to Pose a Challenge
“There are no formal regulatory guidelines aptamers, which specifically addresses the quality expectations of these drugs.,” says a TMR analyst. The regulatory expectation of aptamer-based drugs is still evolving and the development of regulatory guidelines, which would satisfactorily address quality and safety requirements is challenging. However, aptamer modifications can be made to increase half-life or to enhance therapeutic abilities. In addition to this, chemical structure modification of aptamer can also prove to be beneficial.
This information is based on the findings of a report published by Transparency Market Research titled “Aptamers Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019.”